CN101595115B - 有机-氧化砷化合物及其用途 - Google Patents

有机-氧化砷化合物及其用途 Download PDF

Info

Publication number
CN101595115B
CN101595115B CN2007800439892A CN200780043989A CN101595115B CN 101595115 B CN101595115 B CN 101595115B CN 2007800439892 A CN2007800439892 A CN 2007800439892A CN 200780043989 A CN200780043989 A CN 200780043989A CN 101595115 B CN101595115 B CN 101595115B
Authority
CN
China
Prior art keywords
cells
compounds
penicillamine
compound
arsenic oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800439892A
Other languages
English (en)
Chinese (zh)
Other versions
CN101595115A (zh
Inventor
P·J·霍格
P·迪尔达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NewSouth Innovations Pty Ltd
Original Assignee
NewSouth Innovations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006906220A external-priority patent/AU2006906220A0/en
Application filed by NewSouth Innovations Pty Ltd filed Critical NewSouth Innovations Pty Ltd
Publication of CN101595115A publication Critical patent/CN101595115A/zh
Application granted granted Critical
Publication of CN101595115B publication Critical patent/CN101595115B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/74—Aromatic compounds
    • C07F9/76—Aromatic compounds containing hydroxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2007800439892A 2006-11-01 2007-11-01 有机-氧化砷化合物及其用途 Active CN101595115B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006906220 2006-11-01
AU2006906220A AU2006906220A0 (en) 2006-11-01 Arsenoxide compounds and use thereof
PCT/AU2007/001676 WO2008052279A1 (en) 2006-11-01 2007-11-01 Organo-arsenoxide compounds and use thereof

Publications (2)

Publication Number Publication Date
CN101595115A CN101595115A (zh) 2009-12-02
CN101595115B true CN101595115B (zh) 2012-07-18

Family

ID=39343707

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800439892A Active CN101595115B (zh) 2006-11-01 2007-11-01 有机-氧化砷化合物及其用途

Country Status (8)

Country Link
US (2) US8268883B2 (enExample)
EP (1) EP2069371B1 (enExample)
JP (1) JP5301449B2 (enExample)
CN (1) CN101595115B (enExample)
AU (1) AU2007314076B2 (enExample)
CA (1) CA2668010C (enExample)
ES (1) ES2411094T3 (enExample)
WO (1) WO2008052279A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2462932A1 (en) 2002-01-07 2012-06-13 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
US20060166208A1 (en) 2002-11-07 2006-07-27 Hogg Philip J Induction of the mitochondrial permeability transition
WO2009043114A1 (en) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Arsenoxide compound and method of use
TWI539493B (zh) 2010-03-08 2016-06-21 黛納羅伊有限責任公司 用於摻雜具有分子單層之矽基材之方法及組合物
US8853438B2 (en) * 2012-11-05 2014-10-07 Dynaloy, Llc Formulations of solutions and processes for forming a substrate including an arsenic dopant
JP2018517744A (ja) * 2015-06-15 2018-07-05 ニューサウス イノベーションズ プロプライアタリー リミティド 有機アルセノキシド化合物とｍＴＯＲ阻害剤の組合せ医薬
CA3136647A1 (en) 2019-04-12 2020-10-15 Centenary Institute Of Cancer Medicine And Cell Biology Conjugates and their use as imaging agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1742100A (zh) * 2002-11-07 2006-03-01 单检索有限公司 对线粒体通透性转换的诱导
US7074766B1 (en) * 1999-09-20 2006-07-11 New South Innovations Pty Limited Substantially cell membrane impermeable compound and use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2370092A (en) 1942-05-04 1945-02-20 Parke Davis & Co Organic amine derivatives and method of obtaining same
US2409291A (en) 1942-05-19 1946-10-15 Squibb & Sons Inc Chemotherapeutic sulfanilamide derivatives
US2465308A (en) 1946-11-27 1949-03-22 Hoffmann La Roche Arsenoso compounds and method of preparation
US2664432A (en) 1947-01-28 1953-12-29 Ernst A H Friedheim Heterocyclic metal and sulfur organic compounds
US2553515A (en) 1948-12-11 1951-05-15 Hoffmann La Roche N-(p-arsenoso-benzyl)-urea
US2951766A (en) 1957-07-15 1960-09-06 Le Roy A White Antiseptic plastic
BE786573A (fr) * 1971-07-20 1973-01-22 Hoechst Ag Medicament a base de composes arsenicaux organiques et de derives du benzimidazole
FR2640269B1 (fr) 1988-12-13 1991-03-15 Maes Ludo Composes organometalliques, leurs modes de preparation et compositions pharmaceutiques les contenant
US5270196A (en) 1989-10-20 1993-12-14 Bristol-Myers Squibb Company Arylsulfatase from streptomyces
FR2684382B1 (fr) 1991-12-02 1994-10-21 Rhone Merieux Medicaments et preparations pures de dichlorhydrate de melarsomine, leur procede d'obtention et produits intermediaires obtenus.
WO1998051297A1 (en) 1997-05-14 1998-11-19 The University Of New Mexico Inhibition of cell surface protein disulfide isomerase
WO1999018798A1 (en) 1997-10-15 1999-04-22 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
WO2000026370A2 (en) 1998-11-03 2000-05-11 Mitokor Adenine nucleotide translocator (ant) fusion proteins and uses thereof
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
CA2375542A1 (en) 1999-06-22 2000-12-28 James A. Dykens Compositions and methods for assaying subcellular conditions and processes energy transfer
AUPR379801A0 (en) 2001-03-19 2001-04-12 Unisearch Limited Use of a substantially cell membrane impermeable compound for treating arthritis
AUPR598901A0 (en) * 2001-06-28 2001-07-19 Unisearch Limited Inhibition of angiogenesis by targeting protein tyrosine phosphatases
AUPR874601A0 (en) * 2001-11-08 2001-11-29 Unisearch Limited Selective targeting of apoptotic cells
EP2462932A1 (en) * 2002-01-07 2012-06-13 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
US20060166208A1 (en) * 2002-11-07 2006-07-27 Hogg Philip J Induction of the mitochondrial permeability transition
WO2009043114A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Arsenoxide compound and method of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074766B1 (en) * 1999-09-20 2006-07-11 New South Innovations Pty Limited Substantially cell membrane impermeable compound and use thereof
CN1742100A (zh) * 2002-11-07 2006-03-01 单检索有限公司 对线粒体通透性转换的诱导

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pierre J.Dilda,et al..Optimization of the Antitumor Efficacy of a Synthetic Mitochondrial Toxin by Increasing the Residence Time in the Cytosol.《Journal of Medicinal Chemistry》.2009,第52卷(第20期),6209,6213-6215. *

Also Published As

Publication number Publication date
EP2069371B1 (en) 2013-03-13
CA2668010A1 (en) 2008-05-08
JP2010508245A (ja) 2010-03-18
US8268883B2 (en) 2012-09-18
AU2007314076B2 (en) 2012-07-19
AU2007314076A1 (en) 2008-05-08
US20130041027A1 (en) 2013-02-14
EP2069371A4 (en) 2010-02-10
US9765101B2 (en) 2017-09-19
JP5301449B2 (ja) 2013-09-25
ES2411094T3 (es) 2013-07-04
US20100041749A1 (en) 2010-02-18
CN101595115A (zh) 2009-12-02
EP2069371A1 (en) 2009-06-17
CA2668010C (en) 2015-03-24
WO2008052279A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
CN101595115B (zh) 有机-氧化砷化合物及其用途
CA3041563C (en) Pyrimidin-2-amine derivatives and pharmaceutical compositions thereof useful as inhibitors of cyclin-dependent kinase 12 (cdk12)
US20080090793A1 (en) Compounds and methods for the treatment of cancer
US20230265070A1 (en) Novel usp7 inhibitors for treating multiple myeloma
CN104797565A (zh) 新的苯磺酰胺噻唑化合物
CN103370308A (zh) 缩氨基硫脲化合物和在癌症治疗中的用途
CN103930166A (zh) p62小分子化学抑制剂
AU2017205389B2 (en) Benzothiazole amphiphiles
JP4426456B2 (ja) ミトコンドリア膜透過性遷移の誘導
US11306063B2 (en) Heterocyclic naphthoquinones derivatives for use in the treatment of cancers including Cushing disease
MX2011001800A (es) Compuestos de arsenico organico y metodos para el tratamiento de cancer.
EP1379233A1 (en) Use of a substantially cell membrane impermeable compound for treating arthritis
ES2877809T3 (es) Terapia combinada para enfermedades proliferativas
JP2023512822A (ja) タンパク質分解のための化合物、組成物および方法
JP2022538074A (ja) タンパク質分解のための化合物、組成物、および方法
CN101395166B (zh) 用于治疗癌症的化合物和方法
US20160280701A1 (en) Inhibitors of collagen prolyl 4-hydroxylase
US9670197B2 (en) Small molecule modifiers of the Hec1-Nek2 interaction in G2/M
WO2009043114A1 (en) Arsenoxide compound and method of use
US20210251995A1 (en) Pyrazolopyrimidine compounds as adenosine receptor antagonists
AU778781B2 (en) A substantially cell membrane impermeable compound and use thereof
AU2011204901B2 (en) Compounds and methods for treatment of cancer
AU2005201144B9 (en) A substantially cell membrane impermeable compound and use thereof
GB2563396A (en) Chemical Compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant